In Depth 11 Oct 2021
A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can…
Celyad
- Latest Posts
News and Trends 12 Nov 2019
First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors
The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid…
In Depth 15 Oct 2019
Four New Technologies That Will Change Cancer Treatment
New approaches to tame the immune system in the fight against cancer are getting us closer to a future where…
News and Trends 14 Nov 2018
CAR-T Promise for Patients with Solid Tumors
A new CAR-T cancer therapy from the Belgian company Celyad has shown early positive results against solid tumors in two…
ADVERTISEMENT
Interview 13 Jun 2018
CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead
CAR-T cell therapy has been able to effectively treat cancer in some patients for whom all other treatment options were…
News and Trends 23 May 2018
Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race
Update (23/05/2018): Investors have fully subscribed Celyad's global offering of shares on NASDAQ and Euronext Paris, making the company raise…
News and Trends 19 Apr 2018
“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“
Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to…
News and Trends 23 Jan 2018
Another Huge Acquisition Sees CAR-T Stocks Jump – Except for Celyad
Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire Juno: Cellectis rides the wave…
News and Trends 29 Aug 2017
Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks
European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the…
In Depth 11 Jul 2017
Regenerating the Body With Stem Cells – Hype or Hope?
When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem…
ADVERTISEMENT
News and Trends 11 May 2017
Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy
Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with…
News and Trends 2 May 2017
Novartis Gains Access to Celyad’s allogenic CAR-T cell patents
Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license…
Interview 20 Apr 2017
Which EU Immuno-Oncology Company are you Cheering for?
Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways…
Best in Biotech 15 Mar 2017
What are the Best Countries to Recruit Biotech Talents in 2017?
Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look…
Infographics 13 Feb 2017
Infographic: What’s in Europe’s Immuno-oncology Pipeline?
While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer.…
Best in Biotech 3 Jan 2017
10 Hot European Biotechs to Observe in 2017 🚀
New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This…
ADVERTISEMENT
News and Trends 23 Dec 2016
The 8 Biggest Biotech Medical Fails of 2016 in Europe
Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of…
News and Trends 6 Dec 2016
How is European Immuno-Oncology fighting Blood Cancer?
From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's edition of the American Society…
News and Trends 21 Nov 2016
Celyad’s Autologous CAR-T Therapy enters Phase Ib
Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80%…
News and Trends 29 Sep 2016
Debunking the Immuno-Oncology Hype: is it as good as it sounds?
CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters…